Upstream Bio has dosed the first subject in the Phase II trial of verekitug in individuals with chronic obstructive pulmonary disease (COPD).

Beacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova.

A panel at CTO East Coast discussed the regulatory changes impacting oncology trials and how these can be managed.

Arrowhead has dosed the first participant in the Phase III YOSEMITE trial of zodasiran, under development for treating HoFH.

UroGen Pharma has completed the enrolment of subjects in its Phase III UTOPIA trial, which is evaluating UGN-103 for intravesical solution.

Taiho Pharmaceutical’s investigational Duchenne muscular dystrophy (DMD) therapy, pizuglanstat, has shown no benefit in a Phase III trial.

Jasper Therapeutics’ stock has dropped after it announced it was investigating the impact of a faulty batch of its investigational antibody therapy dosed in a Phase Ib/IIa trial.

PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611.

The FDA and the EMA have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib for mCRPC.

PYC Therapeutics is set to begin Part B in its SAD study of the drug candidate, PYC-003, for polycystic kidney disease (PKD) patients.

Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, for C3-glomerulopathy (C3G).

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.